News & Updates
Filter by Specialty:
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023
IMDC score, metastatic sites predict survival in mRCC patients undergoing surveillance
Surveillance of favourable-risk patients with metastatic renal cell carcinoma (mRCC) using risk stratification based on the International mRCC Database Consortium (IMDC) and number of metastatic sites may be done following cytoreductive nephrectomy without initiating systemic therapy, suggests a recent study.
IMDC score, metastatic sites predict survival in mRCC patients undergoing surveillance
30 Jul 2023
Financial toxicity in prostate cancer means less spending on basic goods, leisure
Patients with metastatic prostate cancer who report high financial toxicity tend to spend less on basic goods and leisure activity and use their savings to pay for care, according to the results of a cross-sectional study.
Financial toxicity in prostate cancer means less spending on basic goods, leisure
29 Jul 2023
Niraparib maintenance confers prolonged survival in advanced ovarian cancer
Maintenance therapy with niraparib appears to increase progression-free survival (PFS) in patients with advanced ovarian cancer, irrespective of postoperative residual disease or biomarker status, according to data from the phase III PRIME study.
Niraparib maintenance confers prolonged survival in advanced ovarian cancer
27 Jul 2023
Cilta-cel a new Soc for lenalidomide-refractory MM?
In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.
